Locations:
Search
Treatment may allow patients more time with less toxicity
Promising phase 2 study results
TNF alpha inhibitors: cutaneous side effects and management strategies
Results point to lymphovascular space invasion as marker for poorer prognosis
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Regional integration, process improvement, ongoing study
Even high-risk patients see long-term benefit
Study examines the relationship between outcomes and delay
New study examines rates of downgrading in patients with aggressive prostate cancer
New research elucidates key role of WISP1 protein
Many approaches won’t delay therapy
Advertisement
Advertisement